الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 72 |  |  |
| | | from | 72 | | |
Abstract
The discovery of PCSK9, a key regulator of cholesterol homeostasis, has revolutionized hypercholesterolemia and cardiovascular disease management. It is expressed in various organs, including the skin, and is implicated in the pathogenesis of psoriasis lesion development, and has been shown to be involved in the development of psoriatic lesions.
This study aimed to investigate the association between blood level of PCSK9 as a biomarker in psoriasis and risk of development of atherosclerosis.
This study included 60 adult patients with psoriasis vulgaris and 60 healthy age and sex comparable controls recruited from the Dermatology Outpatient Clinic of the Alexandria Main University Hospital. All patients were subjected to full history taking, general physical examination that included blood pressure measurements, calculation of body mass index, full dermatological examination including examination of skin, and cutaneous appendages, calculation of psoriasis area and severity index (PASI) score for each patient. All patients were investigated for serum LDL-cholesterol, triglycerides, cholesterol, HDL, fasting blood glucose level, and PCSK9 using the ELISA kit according to the manufacturer’s recommendation. Based on the patients’ history, and clinical data, Framingham risk score was calculated to estimate the 10 year cardiovascular risk of an individual was done.